North America to Hold the Lion’s Share in the Blood Glucose Lancets Market

Introduction

A blood glucose lancet is defined as a medical device, similar to a scalpel, which has a double-edged blade. The blade is used to pierce the skin to collect blood samples that are further used in diabetes patients to diagnose blood glucose levels. These lancets are regularly used by diabetic patients to track their blood glucose levels. Generally, these blood glucose lancets are disposable and portable, and find application in in-home healthcare as well as in hospitals or diagnostic laboratories.

The market’s most significant driver is the increasing prevalence of diabetes and surging inclination toward home-based healthcare diagnostics. Rising use of disposable blood glucose lancets for painless diagnosis of blood sugar levels, hemoglobin, lipid levels, and other important blood components drives the market growth

Key Highlights

• The blood glucose lancets market was valued at USD 1091.3 million in 2019 and is expected to grow with a CAGR of 9.6% during the forecast period on account of the increasing prevalence of diabetes
• The push button lancets segment holds the highest market share owing to its quick, comfortable, pain-free, and adequate blood sample collection capabilities
• The hospital segment dominates the market on account of the rising adoption of blood glucose monitoring devices in hospitals
• North America leads the blood glucose lancets market on account of its high adoption rate by both physicians and patients and easy availability of blood lancets across the region

Competitive Players

1. HTL-STREFA S.A
2. Roche Diagnostics
3. Becton
4. Er Dickinson and Company
5. Terumo Corporation
6. Own Mumford
7. Ypsomed
8. Braun Melsungen
9. ARKRAY
10. Sarstedt
11. SteriLance Medical
12. Dexcom

Recent Developments

• November 2023- DarioHealth Corp., a prominent global digital health market player, introduced an innovative blood sugar meter specifically designed for Apple iPhone 15 users. This device aims to enhance the interaction between the company and its current and potential customers.
• October 2023- Philip Morris International (PMI) announced its intentions to introduce a tobacco-free product named LEVIA in the near future. LEVIA is composed of a cellulose-derived substance, specifically a natural plant fiber. LEVIA, in contrast to cigarettes, is devoid of tobacco but does contain nicotine.

Segmentation

1. By Type
   1. Push-button Lancets
   2. Pressure-activated Lancets
   3. Side-activated Lancets
2. By End-User
   1. Hospitals and Clinics
   2. Diagnostics Center
   3. Home Healthcare
   4. Others